Evercore ISI started coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued an outperform rating on the stock.
Other equities research analysts have also issued reports about the stock. Citigroup started coverage on shares of Apellis Pharmaceuticals in a research report on Monday. They set a buy rating and a $23.00 target price on the stock. J P Morgan Chase & Co started coverage on shares of Apellis Pharmaceuticals in a research report on Monday. They set an overweight rating and a $31.00 target price on the stock.
Shares of Apellis Pharmaceuticals (NASDAQ APLS) traded up $0.39 during midday trading on Monday, hitting $13.99. 407,900 shares of the company’s stock traded hands, compared to its average volume of 129,995. Apellis Pharmaceuticals has a 52 week low of $12.45 and a 52 week high of $15.41.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://weekherald.com/2017/12/08/evercore-isi-begins-coverage-on-apellis-pharmaceuticals-apls.html.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.
Receive News & Ratings for Apellis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.